Abbott announced that the FDA has approved its Aveir VR single-chamber leadless pacemaker for the treatment of bradycardia, according to a company press release.
The Aveir VR is implanted directly in the right ventricle via a minimally invasive procedure. The device features a unique mapping capability to determine correct placement before final implantation. It also features increased projected battery life that can last up to two times longer than other currently commercially available leadless pacemakers, according to the release.
The Aveir VR is the only leadless pacemaker designed to be